Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power.

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

For decades, software developers have been slipping jokes into their work. One of the most enduring, clever, and geekily satisfying inside jokes has been hiding in plain sight: the recursive acronym.

And other pharma news rounded up from around the Pharmalot campus, as told to you by the Pharmalittle newsletter ...

Plume is bringing real-world yield to Solana with the rollout of its Nest vaults, giving the network’s users direct access to ...

Instead of a single, massive LLM, Nvidia's new 'orchestration' paradigm uses a small model to intelligently delegate tasks to ...

Previously, we watched Tim Berners-Lee knit the world together with the Web, giving us pages to browse and links to click. But a web of information is ...

New approaches hurdle biological barriers to attack recalcitrant targets to tackle difficult-to-treat and recurrent cancers.

Ethereum’s Fusaka upgrade introduces PeerDAS, new blob economics and key UX improvements that push deeper into the Surge, ...

Two important architectures are Artificial Neural Networks and Long Short-Term Memory networks. LSTM networks are especially useful for financial applications because they are designed to work with ...